viewStarpharma Holdings Limited

Starpharma Holdings cancer drug delivery system improves anti-cancer effect in breast cancer


Starpharma Holdings (ASX: SPL, OTCQX: SPHRY) has demonstrated that its dendrimer-docetaxel formulation is more effective than docetaxel, a leading chemotherapy drug.

The latest study looked at a breast cancer xenograft in mice to examine Starpharma’s drug delivery program for docetaxel.

Mice were implanted with breast cancer cells that were allowed to grow to a predetermined tumour size, following which 10 mice per group were dosed with either dendrimer-docetaxel, docetaxel or saline on days 1, 8 and 15.
The tumour volume was then assessed.

Of the animals treated with the dendrimer-docetaxel formulation, 60% had no evidence of tumour at 94 days.

In comparison, 100% of animals treated with docetaxel alone showed significant tumour regrowth or recurrence by day 60.

Results from the study show a strong enhancement of the anti-cancer effect from Starpharma’s dendrimer-docetaxel formulation compared to docetaxel alone.

The improved efficacy of the dendrimer-docetaxel formulation is believed to stem from the longer circulating half-life, the extended release of docetaxel from the dendrimer and the targeting of the dendrimer construct to the tumour tissue.

This study builds on a previous experiment which found that the addition of the dendrimer formulation to docetaxel improved water solubility.

Improved water solubility could allow for the removal of formulation components in existing drugs that are thought to cause severe allergic reactions and fluid retention in some patients.

Quick facts: Starpharma Holdings Limited

Price: 1.19 AUD

Market: ASX
Market Cap: $443.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Proactive analyst Ryan Long talks tin prices used in economic studies

Proactive mining analyst Dr Ryan Long takes a look at the tin price used by companies in economic studies. He says net present value and internal rate of return are two of the most commonly used metrics to compare the value of different mining projects but the fatal flaws with using these...

10 minutes ago

2 min read